Skip to main
PMN
PMN logo

PMN Stock Forecast & Price Target

PMN Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ProMIS Neurosciences Inc. is showing promising clinical advancements with its lead candidate, PMN310, which has demonstrated favorable safety profiles and pharmacokinetic properties in Phase 1a trials, reinforcing the rationale for its targeted approach to neurodegenerative diseases. Additionally, the dual selectivity profile of PMN267 is expected to enhance its therapeutic potential across a range of TDP-43-driven conditions, including ALS and frontotemporal dementia, thus broadening the company's market prospects. The positive biomarker data obtained from these candidates may justify continued investment as the company approaches final 12-month data releases, suggesting a robust pipeline that addresses significant unmet medical needs in neurodegeneration.

Bears say

ProMIS Neurosciences faces a challenging outlook due to its reliance on research that has not demonstrated consistent positive results in animal models, which may hinder investor confidence in the effectiveness of its therapies. The company is also likely to encounter significant risks related to future partnerships and market competition, potentially affecting its overall market uptake and revenue generation. Additionally, concerns regarding possible near-term dilution risks could further impact its financial stability and attractiveness to investors.

PMN has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ProMIS Neurosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ProMIS Neurosciences Inc (PMN) Forecast

Analysts have given PMN a Strong Buy based on their latest research and market trends.

According to 3 analysts, PMN has a Strong Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ProMIS Neurosciences Inc (PMN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.